{"component": "definition", "props": {"groups": [{"size": 60, "snippet_links": [], "samples": [{"hash": "kD8m6W1FHt8", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?991+ful+HB1819H1+pdf", "label": "legacylis.virginia.gov", "score": 18.2345180511, "published": false}, {"hash": "jqqYLpueQSd", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?961+ful+SB34S1+pdf", "label": "legacylis.virginia.gov", "score": 18.2345180511, "published": false}, {"hash": "6Vhqizlt3Rl", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?971+ful+SB1190+pdf", "label": "legacylis.virginia.gov", "score": 17.9384098053, "published": false}], "snippet": "means the taking of two or more ingredients and fabricating them into a single", "hash": "d766edd2e64f87fbb539a6e972bac962", "id": 1}, {"size": 46, "snippet_links": [{"key": "medically-necessary", "type": "clause", "offset": [26, 45]}, {"key": "according-to", "type": "definition", "offset": [126, 138]}, {"key": "an-individual", "type": "clause", "offset": [176, 189]}], "samples": [{"hash": "3VqkNTldWRC", "uri": "/contracts/3VqkNTldWRC#compound", "label": "Agreement of Coverage", "score": 28.1062068939, "published": true}, {"hash": "aAHZnN98OfW", "uri": "/contracts/aAHZnN98OfW#compound", "label": "Epo Agreement of Coverage", "score": 26.835729599, "published": true}, {"hash": "2nipX0p8ghd", "uri": "/contracts/2nipX0p8ghd#compound", "label": "Agreement of Coverage", "score": 26.835729599, "published": true}], "snippet": "means to form or create a Medically Necessary customized composite product by combining two (2) or more different ingredients according to a Physician\u2019s specifications to meet an individual patient\u2019s need.", "hash": "40ff46fceb03b8fd2f070b4666bc9211", "id": 2}, {"size": 33, "snippet_links": [], "samples": [{"hash": "9uAozd7afCt", "uri": "/contracts/9uAozd7afCt#compound", "label": "Research Collaboration Agreement (ArriVent BioPharma, Inc.)", "score": 35.86926651, "published": true}, {"hash": "bLQKtSbDx2T", "uri": "/contracts/bLQKtSbDx2T#compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 35.0095825195, "published": true}, {"hash": "cqepFxHXj6a", "uri": "/contracts/cqepFxHXj6a#compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 34.9274482727, "published": true}], "snippet": "means [***].", "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"size": 29, "snippet_links": [{"key": "appendix-1", "type": "clause", "offset": [255, 265]}, {"key": "by-pfizer", "type": "clause", "offset": [309, 318]}, {"key": "for-clarity", "type": "clause", "offset": [335, 346]}, {"key": "not-limited", "type": "clause", "offset": [555, 566]}], "samples": [{"hash": "9UKSM6MoXOX", "uri": "/contracts/9UKSM6MoXOX#compound", "label": "License Agreement", "score": 33.493347168, "published": true}, {"hash": "8BTiZcAhKvm", "uri": "/contracts/8BTiZcAhKvm#compound", "label": "License Agreement", "score": 33.2059211731, "published": true}, {"hash": "gi8YtayxFOM", "uri": "/contracts/gi8YtayxFOM#compound", "label": "License Agreement", "score": 33.1758117676, "published": true}], "snippet": "means (1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin- 3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3- azabicyclo[3.1.0]hexane-2-carboxamide, which has the molecular formula C23H32F3N5O4 and having the structure to be set forth on Appendix 1 attached hereto, as referred to internally by Pfizer as PF-07321332. For clarity, \u201cCompound\u201d includes all forms of (1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]- 3-azabicyclo[3.1.0]hexane-2-carboxamide, including but not limited to, isomers, stereoisomers, diastereomers, tautomers, hydrates, solvates, crystal forms including crystalline forms and co-crystalline forms, amorphous forms, polymorphs, metabolites and prodrugs thereof. Additionally, \u201cCompound\u201d includes all deuterated forms.", "hash": "4dbac8283618729900792cd4e1086f04", "id": 4}, {"size": 28, "snippet_links": [{"key": "pursuant-to", "type": "clause", "offset": [61, 72]}, {"key": "in-anticipation-of", "type": "definition", "offset": [76, 94]}, {"key": "prescription-drug-order", "type": "definition", "offset": [103, 126]}, {"key": "not-limited", "type": "clause", "offset": [142, 153]}, {"key": "intravenous-admixture", "type": "definition", "offset": [169, 190]}, {"key": "this-chapter", "type": "definition", "offset": [260, 272]}, {"key": "modification-of", "type": "clause", "offset": [327, 342]}, {"key": "drug-products", "type": "definition", "offset": [343, 356]}, {"key": "prior-to", "type": "definition", "offset": [357, 365]}], "samples": [{"hash": "cR9lvBBAGKI", "uri": "/contracts/cR9lvBBAGKI#compound", "label": "Definitions for Chapter", "score": 26.699508667, "published": true}, {"hash": "J29hC99fb5", "uri": "/contracts/J29hC99fb5#compound", "label": "Definitions for Chapter", "score": 17.5057029724, "published": true}, {"hash": "aBuTk24L1u8", "uri": "https://apps.legislature.ky.gov/record/09RS/hb297/bill.doc", "label": "apps.legislature.ky.gov", "score": 8.4483232498, "published": false}], "snippet": "or \"compounding\" means the preparation or labeling of a drug pursuant to or in anticipation of a valid prescription drug order including, but not limited to, packaging, intravenous admixture or manual combination of drug ingredients. \"Compounding,\" as used in this chapter, shall not preclude simple reconstitution, mixing, or modification of drug products prior to administration by nonpharmacists;", "hash": "be5fd7828e39c8dcab9127f0cc97cce3", "id": 5}, {"size": 13, "snippet_links": [], "samples": [{"hash": "ef5Slpx7vwc", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/sb27/bill.pdf", "label": "apps.legislature.ky.gov", "score": 15.9122858047, "published": false}, {"hash": "5Xi2k3l6Hq2", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/SB27/SCS1.pdf", "label": "apps.legislature.ky.gov", "score": 15.84416008, "published": false}, {"hash": "dYSREQ06GZt", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/hb806/orig_bill.pdf", "label": "apps.legislature.ky.gov", "score": 15.7817811966, "published": false}], "snippet": "or \"compounding\" means the preparation or labeling of a drug", "hash": "1a280d0e87014e448f0a070aed9ce4af", "id": 6}, {"size": 12, "snippet_links": [{"key": "dosage-form", "type": "definition", "offset": [117, 128]}], "samples": [{"hash": "gtDGZyY9a53", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?961+ful+CHAP0152+pdf", "label": "lis.virginia.gov", "score": 11.308008194, "published": false}, {"hash": "bpZ2dOcMBF6", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?031+ful+CHAP0509+pdf", "label": "lis.virginia.gov", "score": 11.2819986343, "published": false}, {"hash": "9FTMrobfd1B", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?031+ful+CHAP0995+pdf", "label": "lis.virginia.gov", "score": 11.2121829987, "published": false}], "snippet": "means the taking of two or more ingredients and fabricating them into a single preparation, usually referred to as a dosage form.", "hash": "cfd8f7c9a8f568046fcbed5750546a87", "id": 7}, {"size": 11, "snippet_links": [{"key": "chemical-compound", "type": "definition", "offset": [8, 25]}, {"key": "by-or-under-the-direction-of", "type": "definition", "offset": [100, 128]}, {"key": "term-of-the-research-program", "type": "clause", "offset": [165, 193]}, {"key": "this-agreement", "type": "clause", "offset": [200, 214]}, {"key": "the-original-agreement", "type": "clause", "offset": [319, 341]}], "samples": [{"hash": "68S373CJgzz", "uri": "/contracts/68S373CJgzz#compound", "label": "Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 32.8384666443, "published": true}, {"hash": "jIVDMjaL1N", "uri": "/contracts/jIVDMjaL1N#compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7816562653, "published": true}, {"hash": "aHrGezSDAKR", "uri": "/contracts/aHrGezSDAKR#compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7433261871, "published": true}], "snippet": "means a chemical compound, including salts and prodrugs thereof, which is synthesized and/or tested by or under the direction of VERTEX or its Affiliates during the term of the Research Program under this Agreement, or which was synthesized and/or tested by and/or under the direction of Aurora or its Affiliates under the Original Agreement; which is either a Potentiator or a Corrector, or both; and which [***]", "hash": "3b5203ab7da9bc12d294070158b7f97b", "id": 8}, {"size": 11, "snippet_links": [{"key": "defined-above", "type": "clause", "offset": [3, 16]}, {"key": "the-recitals", "type": "clause", "offset": [20, 32]}], "samples": [{"hash": "hNHKIxYRP10", "uri": "/contracts/hNHKIxYRP10#compound", "label": "License Agreement (CPEX Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "f9b7dvoFxy9", "uri": "/contracts/f9b7dvoFxy9#compound", "label": "License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "eb5fv4w3rv6", "uri": "/contracts/eb5fv4w3rv6#compound", "label": "License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet": "is defined above in the Recitals.", "hash": "101eb9d13dc646a90ee1d04a2b0f62fa", "id": 9}, {"size": 11, "snippet_links": [{"key": "for-the-purpose-of", "type": "definition", "offset": [69, 87]}], "samples": [{"hash": "lygC3wnBpfq", "uri": "https://docs.legis.wisconsin.gov/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 9.5065021515, "published": false}, {"hash": "gmdGCKTXWlS", "uri": "https://docs.legis.wisconsin.gov/2017/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 7.6557154655, "published": false}, {"hash": "bhZBPQL9xR1", "uri": "https://docs.legis.wisconsin.gov/2015/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 5.5044488907, "published": false}], "snippet": "means to mix, combine or put together vari- ous ingredients or drugs for the purpose of dispensing.", "hash": "0489377a6f28727d9130fafeebc693ed", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRY29tcG91bmQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Compound", "size": 2968, "snippet": "means the taking of two or more ingredients and fabricating them into a single", "id": "compound", "examples": ["Except as set forth in Section 5.6, Buyer shall have no obligation or responsibility (express or implied) to use any efforts to achieve any Milestones Events or to develop or commercialize any <strong>Compound</strong> or Product, and may use its discretion to instead pursue the development and commercialization of other products, regardless of their efficacy, safety, competitiveness in the marketplace, patent or other proprietary position, or market potential relative to any <strong>Compound</strong> or Product.", "No <strong>Compound</strong> or Product is disclosed in or claimed or covered by any of the [***] Patents."], "related": [["licensed-compound", "Licensed Compound", "Licensed <strong>Compound</strong>"], ["collaboration-compound", "Collaboration Compound", "Collaboration <strong>Compound</strong>"], ["lead-compound", "Lead Compound", "Lead <strong>Compound</strong>"], ["compounds", "Compounds", "<strong>Compounds</strong>"], ["licensed-compounds", "Licensed Compounds", "Licensed <strong>Compounds</strong>"]], "related_snippets": [], "updated": "2026-05-16T04:22:31+00:00"}, "json": true, "cursor": ""}}